A Comprehensive Evaluation of the Disease-Modifying Effects of Tafamidis in Patients with Transthyretin Type Familial Amyloid Polyneuropathy

被引：0
|
作者：
Coelho, Teresa
Maia, Luis
da Silva, Ana Martins
Cruz, Marcia Waddington
Plante-Bordeneuve, Violaine
Lozeron, Pierre
Suhr, Ole B.
Campistol, Josep
Conceicao, Isabel
Schmidt, Hartmut
Trigo, Pedro
Packman, Jeff
Grogan, Donna R.
机构：
来源：
NEUROLOGY | 2011年 / 76卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A111 / A111
页数：1
相关论文
共 50 条
  • [31] Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study
    Violaine Planté-Bordeneuve
    Farida Gorram
    Hayet Salhi
    Tarik Nordine
    Samar S. Ayache
    Philippe Le Corvoisier
    Daniel Azoulay
    Cyrille Feray
    Thibaud Damy
    Jean-Pascal Lefaucheur
    Journal of Neurology, 2017, 264 : 268 - 276
  • [32] Serum transthyretin monomer in patients with familial amyloid polyneuropathy
    Sekijima, Y
    Tokuda, T
    Kametani, F
    Tanaka, K
    Maruyama, K
    Ikeda, S
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2001, 8 (04): : 257 - 262
  • [33] Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment
    Ikeda, Tokunori
    Masuda, Teruaki
    Ueda, Mitsuharu
    Yamashita, Taro
    Misumi, Yohei
    Shinriki, Satoru
    Ando, Yukio
    ANNALS OF CLINICAL BIOCHEMISTRY, 2018, 55 (05) : 571 - 575
  • [34] Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial
    Keohane, Denis
    Schwartz, Jeffrey
    Gundapaneni, Balarama
    Stewart, Michelle
    Amass, Leslie
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 (01): : 30 - 36
  • [35] Long-Term Use of Tafamidis in Transthyretin Familial Amyloid Polyneuropathy: A Single Center Experience
    Coelho, Teresa
    Silva, Ana
    Maia, Luis
    Mandel, Francine
    Rosas, Gregory
    Karayal, Onur
    NEUROLOGY, 2013, 80
  • [36] Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study
    Plante-Bordeneuve, Violaine
    Gorram, Farida
    Salhi, Hayet
    Nordine, Tarik
    Ayache, Samar S.
    Le Corvoisier, Philippe
    Azoulay, Daniel
    Feray, Cyrille
    Damy, Thibaud
    Lefaucheur, Jean-Pascal
    JOURNAL OF NEUROLOGY, 2017, 264 (02) : 268 - 276
  • [37] Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin
    Yazaki, M
    Tokuda, T
    Nakamura, A
    Higashikata, T
    Koyama, J
    Higuchi, K
    Harihara, Y
    Baba, S
    Kametani, F
    Ikeda, S
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 274 (03) : 702 - 706
  • [38] Effect of tafamidis on the progression of cardiac involvement in patients with familial amyloid polyneuropathy
    Azevedo Coutinho, M. C.
    Cortez-Dias, N.
    Conceicao, I.
    Cantinho, G.
    Francisco, A. R.
    Guimaraes, T.
    Silva, G. L.
    Menezes, M. N.
    Placido, R.
    Pinto, F. J.
    EUROPEAN HEART JOURNAL, 2015, 36 : 452 - 452
  • [39] Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy
    Buxbaum, Joel N.
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2012, 2 : 165 - 173
  • [40] The effectiveness and value of disease-modifying therapies for transthyretin amyloid cardiomyopathy
    Nikitin, Dmitriy
    Wasfy, Jason H.
    Winn, Aaron N.
    Raymond, Finn
    Shah, Kanya K.
    Kim, Sodam
    Touchette, Daniel R.
    Lee, Woojung
    Richardson, Marina
    Rind, David M.
    Pearson, Steven D.
    Agboola, Foluso
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (03): : 323 - 328
12345